Exploiting a mutation in a key tumor-fighting protein may provide a new opportunity to treat aggressive lung cancers.
A novel targeting strategy may make pave the way for effective cancer immunotherapy against previously ‘undruggable’ targets.
Bortezomib, a drug that inhibits the ‘waste disposal system’ in animal cells, could be used to suppress cell division in cancer.
Drug screen reveals safe, potent, broad-spectrum anticancer compound
The Influenza A virus deliberately enhances levels of the human p53 protein to reduce anti-viral gene and protein expression
probes highlight two hidden binding sites on an anticancer drug target in a
Fluorescent molecular rotors developed by the A*STAR Molecular Engineering Laboratory promise to revolutionize the search for new anticancer drugs
A panel of p53 variants helps scientists confidently identify genes controlled by the master regulator protein
Certain mutations cause a cancer-preventing protein to interfere with cellular pathways and actively drive cancer progression
Tagging genomic elements with fluorescent proteins helps to reveal the secrets behind p53 activity
Pre-treatment with a cell division-blocking drug protects healthy cells from the devastating effects of chemotherapy